Pipeline

Constantly growing pipeline of product opportunities

EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.

Pipeline of product opportunities (including EVT Execute programmes)

Programme
Therapeutic area/Indication
Partner
Status
SKYCovione
Covid-19
SK bioscience
Approved
EVT201
CNS - Insomnia (GABA-A)
Jingxin
Approved
CT7001 / samuraciclib
Oncology (CDK7)
Carrick
Phase IIb
TPM502
Celiac Disease (ND)
Topas Therapeutics
Phase IIa
EVT401
Immunology & Inflammation (P2X7)
CONBA Group
Phase I
TPM203
Pemphigus Vulgaris (ND)
Topas Therapeutics
Phase I
CNTX 6016
Pain (CB2)
Centrexion
Phase I
EVT894
Chikungunya (ND)
Sanofi/NIH
Phase I
EVT801
Oncology (VEGFR3)
Kazia Therapeutics
Phase I
BMS-986419 / EVT8683
Neurodegeneration (elF2b)
Bristol Myers Squibb
Phase I
IMT-009
Oncology (CD161)
Immunitas
Phase I
BAY3401016
Alport Syndrome (Sema3A)
Bayer
Phase I
Encaps-iBeta
Diabetes - beta cell replacement therapy
Sernova
Pre-clinical
EVT075
Antiviral diseases (ND)
Currently unpartnered
Pre-clinical
ND
Neurodegeneration
Bristol Myers Squibb
Pre-clinical
ND
Oncology
Bristol Myers Squibb
Pre-clinical
Various
CNS, Metabolic, Pain ......
>10 further programmes
Pre-clinical
Various
Neurodegeneration
Bristol Myers Squibb
Discovery
Various
Oncology - solid tumours
Bristol Myers Squibb
Discovery
Various
Immunology & Inflammation - Tissue Fibrosis
Pfizer
Discovery
Various
Nephrology
Novo Nordisk
Discovery
Various
Nephrology
Chinook Therapeutics
Discovery
Various
Various
Takeda
Discovery
ND
Oncology
Breakpoint Therapeutics
Discovery
ND
Anti-infectives
Blacksmith
Discovery
INDY inhibitor
Metabolic
Eternygen
Discovery
ND
Fibrotic disease
Fibrocor
Discovery
ND
Gaucher
Centogene
Discovery
Various
Various
Topas Therapeutics
Discovery
ND
Heart failure
UKE
Discovery
Various
Various

LAB282 / LAB150 / Autobahn Labs / beLAB2122 / beLAB1407 / Danube Labs

Discovery
Various
Anti-infectives
>5 programmes
Discovery
Various
Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
>40 further programmes
Discovery
Programme SKYCovione
Therapeutic area/Indication Covid-19
Partner SK bioscience
Status Approved
Programme EVT201
Therapeutic area/Indication CNS - Insomnia (GABA-A)
Partner Jingxin
Status Approved
Programme CT7001 / samuraciclib
Therapeutic area/Indication Oncology (CDK7)
Partner Carrick
Status Phase IIb
Programme TPM502
Therapeutic area/Indication Celiac Disease (ND)
Partner Topas Therapeutics
Status Phase IIa
Programme EVT401
Therapeutic area/Indication Immunology & Inflammation (P2X7)
Partner CONBA Group
Status Phase I
Programme TPM203
Therapeutic area/Indication Pemphigus Vulgaris (ND)
Partner Topas Therapeutics
Status Phase I
Programme CNTX 6016
Therapeutic area/Indication Pain (CB2)
Partner Centrexion
Status Phase I
Programme EVT894
Therapeutic area/Indication Chikungunya (ND)
Partner Sanofi/NIH
Status Phase I
Programme EVT801
Therapeutic area/Indication Oncology (VEGFR3)
Partner Kazia Therapeutics
Status Phase I
Programme BMS-986419 / EVT8683
Therapeutic area/Indication Neurodegeneration (elF2b)
Partner Bristol Myers Squibb
Status Phase I
Programme IMT-009
Therapeutic area/Indication Oncology (CD161)
Partner Immunitas
Status Phase I
Programme BAY3401016
Therapeutic area/Indication Alport Syndrome (Sema3A)
Partner Bayer
Status Phase I
Programme Encaps-iBeta
Therapeutic area/Indication Diabetes - beta cell replacement therapy
Partner Sernova
Status Pre-clinical
Programme EVT075
Therapeutic area/Indication Antiviral diseases (ND)
Partner Currently unpartnered
Status Pre-clinical
Programme ND
Therapeutic area/Indication Neurodegeneration
Partner Bristol Myers Squibb
Status Pre-clinical
Programme ND
Therapeutic area/Indication Oncology
Partner Bristol Myers Squibb
Status Pre-clinical
Programme Various
Therapeutic area/Indication CNS, Metabolic, Pain ......
Partner >10 further programmes
Status Pre-clinical
Programme Various
Therapeutic area/Indication Neurodegeneration
Partner Bristol Myers Squibb
Status Discovery
Programme Various
Therapeutic area/Indication Oncology - solid tumours
Partner Bristol Myers Squibb
Status Discovery
Programme Various
Therapeutic area/Indication Immunology & Inflammation - Tissue Fibrosis
Partner Pfizer
Status Discovery
Programme Various
Therapeutic area/Indication Nephrology
Partner Novo Nordisk
Status Discovery
Programme Various
Therapeutic area/Indication Nephrology
Partner Chinook Therapeutics
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner Takeda
Status Discovery
Programme ND
Therapeutic area/Indication Oncology
Partner Breakpoint Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication Anti-infectives
Partner Blacksmith
Status Discovery
Programme INDY inhibitor
Therapeutic area/Indication Metabolic
Partner Eternygen
Status Discovery
Programme ND
Therapeutic area/Indication Fibrotic disease
Partner Fibrocor
Status Discovery
Programme ND
Therapeutic area/Indication Gaucher
Partner Centogene
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner Topas Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication Heart failure
Partner UKE
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner

LAB282 / LAB150 / Autobahn Labs / beLAB2122 / beLAB1407 / Danube Labs

Status Discovery
Programme Various
Therapeutic area/Indication Anti-infectives
Partner >5 programmes
Status Discovery
Programme Various
Therapeutic area/Indication Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
Partner >40 further programmes
Status Discovery

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 Get in touch with our experts vCard
TOP